A new mammalian display platform enhances antibody discovery for challenging protein targets.

A dysfunctional lymphatic system, described as a clogging of the brain’s sink, may explain why immunotherapies fail in some Alzheimer’s patients.

In this workshop, you will learn how to measure protein interactions using Octet bio-layer interferometry.

A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.

Learn more about environmentally-friendly antibodies that deliver superior performance.

Recent data show that the drug bamlanivimab, also known as LY-CoV555, does not appear to help those with severe cases of COVID-19, but trials continue for milder cases.

Eli Lilly reports a 72 percent reduction in hospitalization risk among patients who received its monoclonal antibody compared to those who received a placebo.

Testing out combinations of antiviral proteins from llamas could help researchers create potent virus-neutralizing multimers.

Experts will discuss potential neutralizing antibodies currently under investigation for SARS-CoV-2 treatment.

In record time, scientists have gone from harvesting antibodies against SARS-CoV-2 from survivors of coronavirus infections to testing the antibodies’ safety as a drug in humans.

The virus’s tool for prying open host cells is coated in a protective armor of sugar—but gaps may offer vulnerability to disruption by antibodies.

The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.

REGN-EB3 and mAb114 reduced mortality in a clinical trial carried out during the ongoing outbreak in Democratic Republic of Congo.

Executives at a biotech that develops new antibodies argue that Ram Sasisekharan didn’t come up with the structures for at least two experimental therapies that his group has described.

The scientist and clinician helped develop a new form of cancer therapy, using a monoclonal antibody to treat head, neck, colorectal, and lung cancers.

The study will examine the efficacy of four drugs—an antiviral and three monoclonal antibodies—that are already being used to treat patients in Democratic Republic of Congo.

Some patients could suppress the virus without antiretroviral therapy for months after the drug infusions.

The number of cases in Democratic Republic of Congo’s latest outbreak of the virus has now surpassed 100.  

The monoclonal antibody, known as mAb114, is likely to be used in the current Ebola outbreak in DRC.